CD133 expression is associated with less DNA repair, better response to chemotherapy, and survival in ER-positive/ER-negative breast cancer

被引：0
|
作者：
Sato, Takumi
Oshi, Masanori
Lee, Jing
Roy, Arya M.
Chida, Kohei
Endo, Itaru
Obayashi, Masato
Takabe, Kazuaki
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 06期
关键词：
D O I：
10.1158/1538-7445.AM2024-2520
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2520
引用
收藏
页数：2
相关论文
共 50 条
  • [31] High expression of cyclin D1 is associated to high proliferation rate and increased risk of mortality in women with ER-positive but not in ER-negative breast cancers
    Cecilia Ahlin
    Claudia Lundgren
    Elin Embretsén-Varro
    Karin Jirström
    Carl Blomqvist
    M. -L. Fjällskog
    Breast Cancer Research and Treatment, 2017, 164 : 667 - 678
  • [32] High expression of cyclin D1 is associated to high proliferation rate and increased risk of mortality in women with ER-positive but not in ER-negative breast cancers
    Ahlin, Cecilia
    Lundgren, Claudia
    Embretsen-Varro, Elin
    Jirstrom, Karin
    Blomqvist, Carl
    Fjallskog, M. -L.
    BREAST CANCER RESEARCH AND TREATMENT, 2017, 164 (03) : 667 - 678
  • [33] Acid ceramidase 1 expression correlates with a better prognosis in ER-positive breast cancer
    Ruckhaeberle, E.
    Holtrich, U.
    Engels, K.
    Hanker, L.
    Gaetje, R.
    Metzler, D.
    Karn, T.
    Kaufmann, M.
    Rody, A.
    CLIMACTERIC, 2009, 12 (06) : 502 - 513
  • [34] Endo Predict predicts for the response to neoadjuvant chemotherapy in ER-positive, HER2-negative breast cancer
    Bertucci, Francois
    Finetti, Pascal
    Viens, Patrice
    Birnbaum, Daniel
    CANCER LETTERS, 2014, 355 (01) : 70 - 75
  • [35] High spermidine expression is associated with high cell proliferation and worse survival but respond better to immunotherapy in ER-positive/HER2-negative breast cancer
    Jehan, Faisal S.
    Oshi, Masanori
    Endo, Itaru
    Takabe, Kazuaki
    ANNALS OF SURGICAL ONCOLOGY, 2024, 31 (01) : S49 - S49
  • [36] PAM50 for prediction of response to neoadjuvant chemotherapy for ER-positive breast cancer
    Ohara, Ako Matsushita
    Naoi, Yasuto
    Shimazu, Kenzo
    Kagara, Naofumi
    Shimoda, Masafumi
    Tanei, Tomonori
    Miyake, Tomohiro
    Kim, Seung Jin
    Noguchi, Shinzaburo
    BREAST CANCER RESEARCH AND TREATMENT, 2019, 173 (03) : 533 - 543
  • [37] PAM50 for prediction of response to neoadjuvant chemotherapy for ER-positive breast cancer
    Ako Matsushita Ohara
    Yasuto Naoi
    Kenzo Shimazu
    Naofumi Kagara
    Masafumi Shimoda
    Tomonori Tanei
    Tomohiro Miyake
    Seung Jin Kim
    Shinzaburo Noguchi
    Breast Cancer Research and Treatment, 2019, 173 : 533 - 543
  • [38] Neoadjuvant chemotherapy in ER-positive Early Breast Cancer: predictive factors of response and outcome
    Kouadri, N.
    Boudersa, A.
    Bouguetaya, A.
    Djedi, H.
    BREAST, 2023, 68 : S65 - S65
  • [39] Abundance of tumor-infiltrating lymphocytes is associated with pathologic complete response to neoadjuvant chemotherapy but not with survival in ER-positive/HER2-negative breast cancer
    Wu, Rongrong
    Nagahashi, Masayuki
    Oshi, Masanori
    Miyoshi, Yasuo
    Ishikawa, Takashi
    Takabe, Kazuaki
    CANCER RESEARCH, 2023, 83 (05)
  • [40] Prognostic ability of CD44 expression in ER-positive breast cancer.
    Gokmen-Polar, Yesim
    Badve, Sunil S.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
12345